immuno-oncology

News

TIGIT underwhelms again as Novartis ducks out

The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered

News

EMA starts review of GSK’s Jemperli in endometrial cancer

GSK has moved a step closer to approval of its cancer immunotherapy Jemperli as a first-line treatment for endometrial cancer in the EU.

News

Merck, Moderna cue up phase 3 trials for mRNA cancer shot

Moderna and partner Merck & Co have fleshed out the data from their clinical trial of personalised mRNA vaccine for melanoma, saying the results support the start of a

News

GSK, Merck in endometrial cancer face-off

GSK and Merck & Co have both reported new clinical data with the PD-1 checkpoint inhibitors, seeking an edge in the first-line treatment of advanced endometrial cancer

News

NICE backs Keytruda for incurable cervical cancer via CDF

Hundreds of NHS patients with an incurable form of cervical cancer will be able to get treatment using a combination regimen based on Merck & Co/MSD’s cancer immunothe

News